White Sandoz logo on blue background

Sandoz spin-off

Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.

Read more

Latest News

Mar 21, 2023

Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

Mar 09, 2023

Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines

Feb 20, 2023

Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors
View More

Media Releases

Find announcements about Sandoz products, programs and company updates.

Media Library

Visit the Sandoz media resource center to view and download media resources including documents, images and videos.

Media Contacts

Find contacts at Sandoz for media and journalist inquiries.

Novartis Annual Reporting Suite

Access and download our integrated report, annual regulatory filings, and other disclosures.

Novartis Financial Data

Novartis provides the following information on the Group's strong financial performance since its creation in 1996.
Sandoz Leadership
Sandoz Biosimilar Portfolio and Pipeline